Evommune Inc
Research Evommune Inc (EVMN) on Bullrun: market cap USD 500.33M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEVMN
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 500.33M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 32.25M
- Free cash flow-USD 20.50M
Valuation Snapshot
latest market cap is USD 500.33M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 13.00M | -USD 68.87M | -USD 76.68M | n/a | -11.22 | USD 44.06M | USD 1.71M | USD 205.57M |
| FY2024 | USD 7.00M | -USD 66.81M | -USD 58.28M | n/a | -45.29 | USD 16.26M | USD 1.02M | -USD 144.24M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 500.33M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 539.69M | n/a | n/a | n/a |
About Evommune Inc
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Evommune Inc's market cap?
Evommune Inc's market capitalization is USD 500.33M.
What does Evommune Inc do?
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.